ANKTIVA plus BCG meets primary endpoint in randomized BCG-naive NMIBC trial
RCT · Business Wire · 2026-11-09. Number 3 in the UrologyWatch Top 5 for November 16, 2026.
The randomized QUILT-2.005 trial of ANKTIVA (nogapendekin alfa inbakicept) added to BCG met its primary endpoint in patients with BCG-naive non-muscle invasive bladder cancer, according to a company announcement; detailed results were not reported.
Why it matters: A positive randomized readout in the BCG-naive setting could expand use of this combination beyond the BCG-unresponsive population already approved.
Limitation: Topline company announcement; detailed efficacy and safety data not yet available.
Source: Business Wire
Loading today's edition…